The rise of Sildenafil initially fueled significant expansion in the medicinal sector, creating a understanding of substantial returns. However, placing capital in companies solely reliant on top-selling drugs like the erectile dysfunction pill presents significant dangers. Intellectual property end has led off-brand challenge, decreasing sales seg

The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on novel therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the possibility for game-changing treatments and impressive returns is clear, the linked risks are also considerable. Many o